Abstract 96P
Background
Flot (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is the standard regimen for perioperative chemotherapy in locally advanced gastric cancer. Preoperative chemotherapy downstages the tumor, increases pathological response. Patients receiving flot are hospitalised for more than a day. This study compares it with dox (docetaxel, oxaliplatin and capecitabine) - a daycare regimen, as capecitabine has already been proven non-inferior to 5-fluorouracil in advanced gastric cancer.
Methods
62 patients were enrolled in this prospective observational study. 31 patients received 4 doses of 2 weekly infusions of 5-fluorouracil- 2600 mg/m2, leucovorin - 200 mg/m2, oxaliplatin - 85 mg/m2, docetaxel- 50 mg/m2 on day 1. Rest 31 received 3 doses of 3 weekly infusions of docetaxel- 60 mg/m2, oxaliplatin - 130 mg/m2 on day 1 and tablet capecitabine -1000 mg/m2 bid for 14 days. Radiological response to chemotherapy were analysed 2 weeks after chemotherapy completion and categorised into stable disease, partial response, progressive disease and complete response according to recist criteria version 1.1. Chi-square test was applied for analysis.
Results
In flot arm, 38.1 % (8) had partial response, 66.7 % (12) had progressive disease, 55 % (11) had stable disease radiologically. In dox arm, 61.9 %(13) had partial response, 33.3 % (6) had progressive disease, 45 % (9) had stable disease radiologically . 3 patients in dox regimen did not have evaluation (1 lost to follow-up; 2 died during the course of treatment). P value obtained was 0.197. The radiological response to chemotherapy was not statistically significant between two groups.
Conclusions
The radiological response to chemotherapy post flot or dox regimen is not statistically different. Dox maybe considered as an alternative regimen to flot in neoadjuvant chemotherapy in locally advanced gastric cancer patients with the advantage being a daycare procedure, requiring less resources and manpower.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02